Read More

Centessa Pharmaceuticals Announced Poster Presentation of First Preclinical Data for LockBody Program at ASCO

Centessa Pharmaceuticals plc (NASDAQ: CNTA), a clinical-stage pharmaceutical company with a Research & Development ("R&D") innovation engine that aims to discover, develop and ultimately deliver impactful medicines to patients, today announced presentation of the first preclinical data for LB101, PD-L1xCD47 LockBody, in a post

CNTA